Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex
Tóm tắt
Từ khóa
Tài liệu tham khảo
Acebron, S. P., Karaulanov, E., Berger, B. S., Huang, Y. L. & Niehrs, C. Mitotic wnt signaling promotes protein stabilization and regulates cell size. Mol. Cell 54, 663–674 (2014).
Atlasi, Y. et al. Wnt signaling regulates the lineage differentiation potential of mouse embryonic stem cells through Tcf3 down-regulation. PLoS Genet. 9, e1003424 (2013).
Clevers, H., Loh, K. M. & Nusse, R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 346, 1248012 (2014).
Green, J. L., Inoue, T. & Sternberg, P. W. Opposing Wnt pathways orient cell polarity during organogenesis. Cell 134, 646–656 (2008).
Grumolato, L. et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev. 24, 2517–2530 (2010).
Katoh, M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J. Oncol. 51, 1357–1369 (2017).
Mirabelli, C. K., Nusse, R., Tuveson, D. A. & Williams, B. O. Perspectives on the role of Wnt biology in cancer. Sci. Signal. 12, https://doi.org/10.1126/scisignal.aay4494 (2019).
Amin, N. & Vincan, E. The Wnt signaling pathways and cell adhesion. Front Biosci. (Landmark Ed.) 17, 784–804 (2012).
Li, V. S. et al. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 149, 1245–1256 (2012).
MacDonald, B. T., Tamai, K. & He, X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9–26 (2009).
Gao, Z. H., Seeling, J. M., Hill, V., Yochum, A. & Virshup, D. M. Casein kinase I phosphorylates and destabilizes the beta-catenin degradation complex. Proc. Natl Acad. Sci. USA 99, 1182–1187 (2002).
Ha, N. C., Tonozuka, T., Stamos, J. L., Choi, H. J. & Weis, W. I. Mechanism of phosphorylation-dependent binding of APC to beta-catenin and its role in beta-catenin degradation. Mol. Cell 15, 511–521 (2004).
Liu, C. et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837–847 (2002).
Stamos, J. L. & Weis, W. I. The beta-catenin destruction complex. Cold Spring Harb. Perspect. Biol. 5, a007898 (2013).
Wu, G., Huang, H., Garcia Abreu, J. & He, X. Inhibition of GSK3 phosphorylation of beta-catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6. PLoS ONE 4, e4926 (2009).
Schatoff, E. M., Leach, B. I. & Dow, L. E. Wnt signaling and colorectal cancer. Curr. Colorectal Cancer Rep. 13, 101–110 (2017).
White, B. D., Chien, A. J. & Dawson, D. W. Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology 142, 219–232 (2012).
Kwong, L. N. & Dove, W. F. APC and its modifiers in colon cancer. Adv. Exp. Med. Biol. 656, 85–106 (2009).
Rowan, A. J. et al. APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits”. Proc. Natl Acad. Sci. USA 97, 3352–3357 (2000).
Schell, M. J. et al. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nat. Commun. 7, 11743 (2016).
Groden, J. et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66, 589–600 (1991).
Kimelman, D. & Xu, W. beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene 25, 7482–7491 (2006).
Xing, Y. et al. Crystal structure of a beta-catenin/APC complex reveals a critical role for APC phosphorylation in APC function. Mol. Cell 15, 523–533 (2004).
Cadigan, K. M. & Waterman, M. L. TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb. Perspect. Biol. 4, https://doi.org/10.1101/cshperspect.a007906 (2012).
Mann, B. et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl Acad. Sci. USA 96, 1603–1608 (1999).
Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990).
Hashimoto, K. et al. Cellular context-dependent consequences of Apc mutations on gene regulation and cellular behavior. Proc. Natl Acad. Sci. USA 114, 758–763 (2017).
Worm, J., Christensen, C., Gronbaek, K., Tulchinsky, E. & Guldberg, P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 23, 5215–5226 (2004).
Moseley, J. B. et al. Regulated binding of adenomatous polyposis coli protein to actin. J. Biol. Chem. 282, 12661–12668 (2007).
Okada, K. et al. Adenomatous polyposis coli protein nucleates actin assembly and synergizes with the formin mDia1. J. Cell Biol. 189, 1087–1096 (2010).
Schlessinger, K., McManus, E. J. & Hall, A. Cdc42 and noncanonical Wnt signal transduction pathways cooperate to promote cell polarity. J. Cell Biol. 178, 355–361 (2007).
Watanabe, T. et al. Interaction with IQGAP1 links APC to Rac1, Cdc42, and actin filaments during cell polarization and migration. Dev. Cell 7, 871–883 (2004).
Caldwell, C. M. & Kaplan, K. B. The role of APC in mitosis and in chromosome instability. Adv. Exp. Med. Biol. 656, 51–64 (2009).
Hulsken, J., Birchmeier, W., Behrens, J. & E-cadherin, A. P. C. compete for the interaction with beta-catenin and the cytoskeleton. J. Cell Biol. 127, 2061–2069 (1994).
Juanes, M. A. et al. Adenomatous polyposis coli nucleates actin assembly to drive cell migration and microtubule-induced focal adhesion turnover. J. Cell Biol. 216, 2859–2875 (2017).
Rusan, N. M. et al. CIN: reviewing roles for APC in chromosome instability. J. Cell Biol. 181, 719–726 (2008).
Tian, X. et al. E-cadherin/beta-catenin complex and the epithelial barrier. J. Biomed. Biotechnol. 2011, 567305 (2011).
Jung, Y. S. et al. TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/beta-catenin signalling. Nat. Cell Biol. 20, 1421–1433 (2018).
Voloshanenko, O. et al. Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nat. Commun. 4, 2610 (2013).
Kishida, M. et al. Axin prevents Wnt-3a-induced accumulation of beta-catenin. Oncogene 18, 979–985 (1999).
Luo, W. & Lin, S. C. Axin: a master scaffold for multiple signaling pathways. Neurosignals 13, 99–113 (2004).
Mazzoni, S. M. & Fearon, E. R. AXIN1 and AXIN2 variants in gastrointestinal cancers. Cancer Lett. 355, 1–8 (2014).
Salahshor, S. & Woodgett, J. R. The links between axin and carcinogenesis. J. Clin. Pathol. 58, 225–236 (2005).
Haraguchi, K. et al. Ajuba negatively regulates the Wnt signaling pathway by promoting GSK-3beta-mediated phosphorylation of beta-catenin. Oncogene 27, 274–284 (2008).
Kim, N. G., Xu, C. & Gumbiner, B. M. Identification of targets of the Wnt pathway destruction complex in addition to beta-catenin. Proc. Natl Acad. Sci. USA 106, 5165–5170 (2009).
Dajani, R. et al. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J. 22, 494–501 (2003).
Ikeda, S. et al. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 17, 1371–1384 (1998).
Kim, S. E. et al. Wnt stabilization of beta-catenin reveals principles for morphogen receptor-scaffold assemblies. Science 340, 867–870 (2013).
Willert, K., Shibamoto, S. & Nusse, R. Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. Genes Dev. 13, 1768–1773 (1999).
Zeng, X. et al. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438, 873–877 (2005).
MacDonald, B. T. & He, X. Frizzled and LRP5/6 receptors for Wnt/beta-catenin signaling. Cold Spring Harb. Perspect. Biol. 4, https://doi.org/10.1101/cshperspect.a007880 (2012).
Zeng, X. et al. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 135, 367–375 (2008).
He, X., Semenov, M., Tamai, K. & Zeng, X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 131, 1663–1677 (2004).
Piao, S. et al. Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta-catenin signaling. PLoS ONE 3, e4046 (2008).
Stamos, J. L., Chu, M. L., Enos, M. D., Shah, N. & Weis, W. I. Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6. Elife 3, e01998 (2014).
Kishida, S. et al. DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. Mol. Cell Biol. 19, 4414–4422 (1999).
Herr, P. & Basler, K. Porcupine-mediated lipidation is required for Wnt recognition by Wls. Dev. Biol. 361, 392–402 (2012).
Zimmerli, D., Hausmann, G., Cantu, C. & Basler, K. Pharmacological interventions in the Wnt pathway: inhibition of Wnt secretion versus disrupting the protein-protein interfaces of nuclear factors. Br. J. Pharm. 174, 4600–4610 (2017).
Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400–416 e411 (2018).
Grigoryan, T., Wend, P., Klaus, A. & Birchmeier, W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev. 22, 2308–2341 (2008).
Harada, N. et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 18, 5931–5942 (1999).
Kim, S. & Jeong, S. Mutation hotspots in the beta-catenin gene: lessons from the human cancer genome databases. Mol. Cells 42, 8–16 (2019).
Hrckulak, D., Kolar, M., Strnad, H. & Korinek, V. TCF/LEF transcription factors: an update from the internet resources. Cancers 8, https://doi.org/10.3390/cancers8070070 (2016).
Orsulic, S. & Peifer, M. An in vivo structure-function study of armadillo, the beta-catenin homologue, reveals both separate and overlapping regions of the protein required for cell adhesion and for wingless signaling. J. Cell Biol. 134, 1283–1300 (1996).
van de Wetering, M. et al. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 88, 789–799 (1997).
Huber, A. H. & Weis, W. I. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell 105, 391–402 (2001).
Valenta, T., Hausmann, G. & Basler, K. The many faces and functions of beta-catenin. EMBO J. 31, 2714–2736 (2012).
Amit, S. et al. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 16, 1066–1076 (2002).
Machin, P. et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum. Pathol. 33, 206–212 (2002).
Liu, J. et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl Acad. Sci. USA 110, 20224–20229 (2013).
Madan, B. et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene 35, 2197–2207 (2016).
Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235–239 (2011).
Wang, X. et al. The development of highly potent inhibitors for porcupine. J. Med Chem. 56, 2700–2704 (2013).
Madan, B. et al. Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy. Bone Res 6, 17 (2018).
Cheng, C. K. et al. Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia. Blood 118, 6638–6648 (2011).
Shi, Y., He, B., You, L. & Jablons, D. M. Roles of secreted frizzled-related proteins in cancer. Acta Pharm. Sin. 28, 1499–1504 (2007).
Uren, A. et al. Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J. Biol. Chem. 275, 4374–4382 (2000).
Gonzalez, D. M. & Medici, D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal 7, re8 (2014).
Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196 (2014).
Fischer, M. M. et al. WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Sci. Adv. 3, e1700090 (2017).
Jimeno, A. et al. A first-in-human phase i study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors. Clin. Cancer Res 23, 7490–7497 (2017).
Moore, K. N. et al. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol. Oncol. 154, 294–301 (2019).
Giraudet, A. L. et al. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer 18, 646 (2018).
Lu, D. et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc. Natl Acad. Sci. USA 108, 13253–13257 (2011).
Tumova, L. et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol. Cancer Ther. 13, 812–822 (2014).
Zhu, Y. et al. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma. Oncotarget 8, 22825–22834 (2017).
Li, Y. et al. Multi-targeted therapy of cancer by niclosamide: a new application for an old drug. Cancer Lett. 349, 8–14 (2014).
Naujokat, C. & Steinhart, R. Salinomycin as a drug for targeting human cancer stem cells. J. Biomed. Biotechnol. 2012, 950658 (2012).
Huang, S. M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614–620 (2009).
Mariotti, L., Pollock, K. & Guettler, S. Regulation of Wnt/beta-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding. Br. J. Pharm. 174, 4611–4636 (2017).
Morrone, S., Cheng, Z., Moon, R. T., Cong, F. & Xu, W. Crystal structure of a Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate recruitment. Proc. Natl Acad. Sci. USA 109, 1500–1505 (2012).
Lau, T. et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 73, 3132–3144 (2013).
Menon, M. et al. A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors. Sci. Rep. 9, 201 (2019).
Mizutani, A. et al. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Sci. 109, 4003–4014 (2018).
Thorne, C. A. et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat. Chem. Biol. 6, 829–836 (2010).
He, T. C. et al. Identification of c-MYC as a target of the APC pathway. Science 281, 1509–1512 (1998).
Jho, E. H. et al. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol. Cell Biol. 22, 1172–1183 (2002).
Tetsu, O. & McCormick, F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422–426 (1999).
Wielenga, V. J. et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am. J. Pathol. 154, 515–523 (1999).
Wolf, D., Rodova, M., Miska, E. A., Calvet, J. P. & Kouzarides, T. Acetylation of beta-catenin by CREB-binding protein (CBP). J. Biol. Chem. 277, 25562–25567 (2002).
Yu, W. et al. β-catenin cooperates with CREB binding protein to promote the growth of tumor cells. Cell Physiol. Biochem 44, 467–478 (2017).
Takemaru, K. I. & Moon, R. T. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J. Cell Biol. 149, 249–254 (2000).
Yang, K. et al. The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies. Lab Invest 96, 116–136 (2016).
Cantu, C. et al. A cytoplasmic role of Wnt/beta-catenin transcriptional cofactors Bcl9, Bcl9l, and Pygopus in tooth enamel formation. Sci. Signal. 10, https://doi.org/10.1126/scisignal.aah4598 (2017).
de la Roche, M., Worm, J. & Bienz, M. The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells. BMC Cancer 8, 199 (2008).
Feng, M. et al. Pharmacological inhibition of beta-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells. Sci. Adv. 5, eaau5240 (2019).
Lyou, Y., Habowski, A. N., Chen, G. T. & Waterman, M. L. Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy. Br. J. Pharm. 174, 4589–4599 (2017).
Hwang, S. Y. et al. Direct targeting of beta-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/beta-catenin signaling. Cell Rep. 16, 28–36 (2016).
Cantu, C. et al. The Pygo2-H3K4me2/3 interaction is dispensable for mouse development and Wnt signaling-dependent transcription. Development 140, 2377–2386 (2013).
Hao, H. X. et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 485, 195–200 (2012).
Horst, D. et al. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res. 72, 1547–1556 (2012).
Jung, Y. S., Jun, S., Lee, S. H., Sharma, A. & Park, J. I. Wnt2 complements Wnt/beta-catenin signaling in colorectal cancer. Oncotarget 6, 37257–37268 (2015).
Jung, Y. S. et al. Deregulation of CRAD-controlled cytoskeleton initiates mucinous colorectal cancer via beta-catenin. Nat. Cell Biol. 20, 1303–1314 (2018).
Koo, B. K. et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488, 665–669 (2012).
Jung, H. Y. et al. PAF and EZH2 induce Wnt/beta-catenin signaling hyperactivation. Mol. Cell 52, 193–205 (2013).
Kim, M. J. et al. PAF-Myc-controlled cell stemness is required for intestinal regeneration and tumorigenesis. Dev. Cell 44, 582–596 e584 (2018).
He, B. et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 24, 3054–3058 (2005).
Benary, U., Kofahl, B., Hecht, A. & Wolf, J. Modeling Wnt/beta-catenin target gene expression in APC and Wnt gradients under wild type and mutant conditions. Front Physiol. 4, 21 (2013).
Goentoro, L. & Kirschner, M. W. Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling. Mol. Cell 36, 872–884 (2009).
Herbst, A. et al. Comprehensive analysis of beta-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/beta-catenin signaling. BMC Genomics 15, 74 (2014).
Scarborough, H. A. et al. AZ1366: an inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Clin. Cancer Res. 23, 1531–1541 (2017).
Phelps, R. A. et al. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell 137, 623–634 (2009).
Johnson, D. E., Ostrowski, P., Jaumouille, V. & Grinstein, S. The position of lysosomes within the cell determines their luminal pH. J. Cell Biol. 212, 677–692 (2016).
Pamarthy, S., Kulshrestha, A., Katara, G. K. & Beaman, K. D. The curious case of vacuolar ATPase: regulation of signaling pathways. Mol. Cancer 17, 41 (2018).
Lawrence, R. E. & Zoncu, R. The lysosome as a cellular centre for signalling, metabolism and quality control. Nat. Cell Biol. 21, 133–142 (2019).
Chi, C. et al. Disruption of lysosome function promotes tumor growth and metastasis in Drosophila. J. Biol. Chem. 285, 21817–21823 (2010).
Hagemann, A. I. et al. In vivo analysis of formation and endocytosis of the Wnt/beta-catenin signaling complex in zebrafish embryos. J. Cell Sci. 127, 3970–3982 (2014).
Taelman, V. F. et al. Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 143, 1136–1148 (2010).
Ding, V. W., Chen, R. H. & McCormick, F. Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J. Biol. Chem. 275, 32475–32481 (2000).
Saito-Diaz, K. et al. APC inhibits ligand-independent Wnt signaling by the clathrin endocytic pathway. Dev. Cell 44, 566–581 e568 (2018).
Cruciat, C. M. et al. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science 327, 459–463 (2010).
Hermle, T., Saltukoglu, D., Grunewald, J., Walz, G. & Simons, M. Regulation of Frizzled-dependent planar polarity signaling by a V-ATPase subunit. Curr. Biol. 20, 1269–1276 (2010).
Stransky, L., Cotter, K. & Forgac, M. The function of V-ATPases in cancer. Physiol. Rev. 96, 1071–1091 (2016).
Cotter, K. et al. The a3 isoform of subunit a of the vacuolar ATPase localizes to the plasma membrane of invasive breast tumor cells and is overexpressed in human breast cancer. Oncotarget 7, 46142–46157 (2016).
Liu, P., Chen, H., Han, L., Zou, X. & Shen, W. Expression and role of V1A subunit of V-ATPases in gastric cancer cells. Int J. Clin. Oncol. 20, 725–735 (2015).
Ohta, T. et al. Expression of 16 kDa proteolipid of vacuolar-type H(+)-ATPase in human pancreatic cancer. Br. J. Cancer 73, 1511–1517 (1996).
Son, S. W. et al. Prognostic significance and function of the vacuolar H+-ATPase subunit V1E1 in esophageal squamous cell carcinoma. Oncotarget 7, 49334–49348 (2016).
Inoue, T. & Forgac, M. Cysteine-mediated cross-linking indicates that subunit C of the V-ATPase is in close proximity to subunits E and G of the V1 domain and subunit a of the V0 domain. J. Biol. Chem. 280, 27896–27903 (2005).
Marshansky, V., Rubinstein, J. L. & Gruber, G. Eukaryotic V-ATPase: novel structural findings and functional insights. Biochim Biophys. Acta 1837, 857–879 (2014).
Kane, P. M. Disassembly and reassembly of the yeast vacuolar H(+)-ATPase in vivo. J. Biol. Chem. 270, 17025–17032 (1995).
Rahman, S. et al. Biochemical and biophysical properties of interactions between subunits of the peripheral stalk region of human V-ATPase. PLoS ONE 8, e55704 (2013).
Sumner, J. P. et al. Regulation of plasma membrane V-ATPase activity by dissociation of peripheral subunits. J. Biol. Chem. 270, 5649–5653 (1995).
Avina-Zubieta, J. A., Galindo-Rodriguez, G., Newman, S., Suarez-Almazor, M. E. & Russell, A. S. Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann. Rheum. Dis. 57, 582–587 (1998).
Bowman, E. J., Graham, L. A., Stevens, T. H. & Bowman, B. J. The bafilomycin/concanamycin binding site in subunit c of the V-ATPases from Neurospora crassa and Saccharomyces cerevisiae. J. Biol. Chem. 279, 33131–33138 (2004).